CatalYm doses first patient in Phase II/III VINCIT trial

​CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.

The post CatalYm doses first patient in Phase II/III VINCIT trial appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

HeartBeam commences pilot study of new 12-lead ECG patch
Inhibrx announces positive interim results from HexAgon trial
Partner Therapeutics secures FDA approval for Bizengri
Latest foreign investment in UK highlights underserved potential of primary care technology
CoMira concludes lease agreement for plant in Sudair Industrial City, Saudi Arabia

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us